Spero Therapeutics (STU:2HA) Accounts Payable & Accrued Expense : €7.63 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics Accounts Payable & Accrued Expense?

Spero Therapeutics's quarterly accounts payable & accrued expense increased from Jun. 2023 (€6.38 Mil) to Sep. 2023 (€9.26 Mil) but then declined from Sep. 2023 (€9.26 Mil) to Dec. 2023 (€7.63 Mil).

Spero Therapeutics's annual accounts payable & accrued expense declined from Dec. 2021 (€13.67 Mil) to Dec. 2022 (€9.05 Mil) and declined from Dec. 2022 (€9.05 Mil) to Dec. 2023 (€7.63 Mil).

Spero Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Spero Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Accounts Payable & Accrued Expense Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

23.16

11.01

13.67

9.05

7.63

Spero Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															9.05	8.82	6.38	9.26	7.63

Spero Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Spero Therapeutics (STU:2HA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

SPRO:USA

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics (STU:2HA) Headlines

No Headlines